NYSE:CTLT - Catalent Stock Price, News, & Analysis

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent Inc (NYSE:CTLT) released its quarterly earnings results on Tuesday, May, 7th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.07. The company earned $617.50 million during the quarter, compared to the consensus estimate of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. The firm's revenue was down 1.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.41 EPS. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Tuesday, August 27th 2019. View Earnings Estimates for Catalent.

Catalent issued an update on its FY 2019 earnings guidance on Tuesday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.5-2.52 billion, compared to the consensus revenue estimate of $2.54 billion.

7 equities research analysts have issued 1 year price targets for Catalent's shares. Their predictions range from $45.00 to $55.00. On average, they expect Catalent's stock price to reach $50.50 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for Catalent.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.

News headlines about CTLT stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the stock's share price in the next several days.

Some companies that are related to Catalent include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA), Alnylam Pharmaceuticals (ALNY) and Loxo Oncology (LOXO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Energy Transfer LP Unit (ET), Horizon Therapeutics (HZNP), Abbott Laboratories (ABT), Exelixis (EXEL), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Ionis Pharmaceuticals (IONS), AbbVie (ABBV), CBL & Associates Properties (CBL) and SunCoke Energy Partners (SXCP).

Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.02%), BlackRock Inc. (9.56%), William Blair Investment Management LLC (2.80%), Champlain Investment Partners LLC (2.69%), FMR LLC (2.38%) and Geode Capital Management LLC (1.02%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Christine Dolan, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Viking Global Investors LP, Voya Investment Management LLC, Macquarie Group Ltd., Morgan Stanley, Marshall Wace LLP, FMR LLC and PNC Financial Services Group Inc.. Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Lazard Asset Management LLC, Bank of Montreal Can, Eagle Asset Management Inc., Westfield Capital Management Co. LP, ArrowMark Colorado Holdings LLC and SG Americas Securities LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $45.37.

Catalent has a market capitalization of $6.61 billion and generates $2.46 billion in revenue each year. The company earns $83.60 million in net income (profit) each year or $1.59 on an earnings per share basis. Catalent employs 10,700 workers across the globe.

The official website for Catalent is http://www.catalent.com.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]